Targets › INSTI
7 programs from 2 companies in 50 trials: 19 Phase 3, 13 Phase 1, 10 Phase 4, 8 Phase 2; Infectious disease, Other, Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: the race on INSTI, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Fostemsavir Envelope polyprotein GP160 inhibitor | INSTI, GP120, CD4 | Phase 3 | HIV Infections; HIV-1-infection; Human Immunodeficiency Virus (HIV); HIV Infections With Multi Drug Resistant Virus | Jan 2027 |
| GSK | Cabotegravir Human immunodeficiency virus type 1 integrase inhibitor | INSTI, INTEGRASE | Phase 3 | HIV Infections; Infection, Human Immunodeficiency Virus; Pre-exposure Prophylaxis; HIV-1 Infected Adults With Controlled Viremia … | Mar 2027 |
| GSK | Dolutegravir Human immunodeficiency virus type 1 integrase inhibitor | INSTI, RTASE, INTEGRASE, RT | Phase 3 | HIV; HIV Infections; HIV-1-infection; Acute HIV Infection … | Mar 2027 |
| GSK | CAB ULA Integrase strand transfer inhibitor (ultra-long-acting formulation) | INSTI | Phase 3 | HIV Infections | Sep 2029 |
| Professor Francois Venter | Delstrigo (DOR/3TC/TDF) Non-nucleoside reverse transcriptase inhibitor (doravirine) with nucleoside reverse transc | INSTI, NNRTI | Phase 3 | HIV-1-infection | – |
| Professor Francois Venter | KOCITAF (DTG/TAF/FTC) Integrase strand transfer inhibitor (dolutegravir) with nucleotide and nucleoside reverse | INSTI | Phase 3 | HIV-1-infection | – |
| GSK | VH4367310 Cabotegravir prodrug | INSTI | Phase 1 | HIV Infections | Dec 2028 |
HIV Infections (24) HIV-1-infection (10) HIV (4) Infection, Human Immunodeficiency Virus (1) Pre-exposure Prophylaxis (1) HIV-1 Infected Adults With Controlled Viremia (1) Pre-Exposure Prophylaxis (PrEP) (1) HIV -1 Infection (1) Hiv (1) Human Immunodeficiency Virus (HIV) (1) HIV Infections With Multi Drug Resistant Virus (1) Acute HIV Infection (1)
small molecule (5), mixed (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.